

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/19, C07K 14/52, A61K 38/19, C12N 5/10, 1/21		A3	(11) International Publication Number: WO 99/33989 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/EP98/08354 (22) International Filing Date: 21 December 1998 (21.12.98) (30) Priority Data: MI97A002865 23 December 1997 (23.12.97) IT MI98A001866 7 August 1998 (07.08.98) IT (71) Applicant (for all designated States except US): FON- DAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): LUSSO, Paolo [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). POLO, Simona [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 26 August 1999 (26.08.99)
(54) Title: RANTES MUTANTS AND THERAPEUTIC APPLICATIONS THEREOF (57) Abstract RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RANTES MUTANTS AND THERAPEUTIC APPLICATIONS THEREOF

The present invention provides RANTES mutants with reduced pro-inflammatory activity, increased HIV-suppressive activity, and antagonistic activity to wild-type chemokines.

Chemokines are small proteins involved in inflammatory mechanisms and in physiologic circulation of hemopoietic cells. Several studies have shown the important role of chemokines in recruiting leucocytes in inflammatory and autoimmune diseases, like rheumatoid arthritis, or during allergic reactions, like in asthma (Schall, T.J. The chemokines. In: The cytokine handbook, A Thompson ed. Academic Press, New York, 1994, p.419-460). Furthermore, some chemokines have been recently identified as potent natural inhibitors of human immunodeficiency virus (HIV) infection (Science 270, 1811-1815, 1995). Chemokines activity is due to their interaction with receptors having different specificity and expressed on the cell surface. Some of these receptors function as co-receptors for HIV-virus (Science 272, 872-877, 1996; Science 272, 1955-1958, 1996). The differential use of such co-receptors, particularly CCR5 the specific receptor for RANTES, MIP-1 α and MIP-1 β , and CXCR4, the SDF-1 specific receptor, represents a major determinant of the biological diversity among HIV strains. HIV-1 strains unable to infect continuous CD4+ T-cell lines, commonly involved in viral transmission and predominating during the asymptomatic phase of the infection, use primarily CCR5 as a co-receptor and are invariably sensitive to inhibition by CCR5-binding chemokines (Nature Med., 3:1259-1265, 1997). The most effective such chemokine, RANTES, is

therefore under investigation for the development of novel anti-HIV therapies (Nature, 383: 400, 1996). RANTES is a chemokine which belongs to the C-C family and is 68 amino acids long. Its sequence has been reported in J. Immunol. (1988).

5 WO 96/17935 discloses RANTES molecules which are modified at the N-terminus through the addition of an amino acid such as methionine, leucine or glutamine, as antagonists of RANTES or MIP-1 α . In particular, the use thereof for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma-atherosclerosis or rheumatoid arthritis is described.

10 Further, Elsner J. et al. in "European Journal of Immunology, Vol. 27, 2892-2898 (1997)", and WO 96/17934, disclose the antagonistic activity of the Met-RANTES peptide.

The use of wild-type RANTES and of other chemokines of the same family in the treatment of allergic diseases, has been also described
15 in WO 94/07521 and WO 94/21277.

WO 97/25350 discloses disaggregated mutants of MIP-1 α or LD78 having HIV suppressive activity, whereas WO 98/13495 discloses human RANTES mutants unable to aggregate under physiologic ionic strength and which exhibit antiviral activity. Surprisingly now, it has been found
20 that the addition of at least one amino acid at the N-terminus, and/or the substitution of one or more amino acids in the N-terminal region comprised between amino acids 1 and 11 of the mature form of the human chemokine RANTES, and/or in the "40's-loop" region, extending from Thr 43 to Asn 46, provides a notably higher efficacy towards different
25 HIV isolates, both in primary mononucleated blood cells and in macrophages, a reduced pro-inflammatory activity and a potent antagonistic activity, as compared to the wild-type molecule. In

particular, the mutants of the invention competitively antagonise wild-type RANTES, MIP-1 α or MIP-1 β , and, with a comparable mechanism, the interaction between the HIV virus and a chemokine receptor. Preferably, one or more of the amino acids: Ser 1, Ser 4, Ser 5, Tyr 3, Asp 6, Tyr 14, Arg 17, Arg 44, Lys 33, Lys 45 and Arg 46 are mutated, with respect to the wild-type human form described in J. Immunol. 141:1018-1025, 1988, as reference molecule. Preferably, the amino acids Ser 1, Ser 4, Ser 5, Tyr 3 are replaced by neutral or hydrophobic amino acids, Asp 6 is replaced by a positively charged amino acid, Tyr 14 by a hydrophobic aromatic, Arg 17, Lys 33, Arg 44, Lys 45 and Arg 46 by a small sized hydrophobic amino acid.

The following mutations are more preferred: Ser 1 with Cys, Ser 4 with Cys, Ser 5 with Cys, Tyr 3 with Ala, Asp 6 with Arg, Tyr 14 with Phe, Arg 17, Lys 33, Arg 44, Lys 45 and Arg 46 with Ala. A first group of mutants according to the invention is characterised by a triple mutation selected from a) Ser 1 with Cys; Ser 5 with Cys; Asp 6 with Arg, or b) Ser 1 with Cys; Ser 5 with Cys; Arg 17 with Ala, or c) Ser 1 with Cys; Ser 5 with Cys; Arg 44 or Lys 45 or Arg 46, with Ala. A second group is characterised by a double mutation selected from a) Ser 1 and Ser 5 with Cys, or b) Ser 1 and Ser 4 with Cys, or c) Ser 1 with Cys and Arg 44 with Ala, or d) Asp 6 with Arg and Arg 44 with Ala. A third group is characterised by a single mutation selected from a) Ser 1 with Cys, b) Tyr 3 with Ala, c) Asp 6 with Arg, d) Tyr 14 with Phe, e) Arg 17 with Ala, f) Lys 33 with Ala, g) Arg 44 with Ala, h) Lys 45 with Ala, i) Arg 46 with Ala. Furthermore, the above mutants can be added with up to two amino acids at the N-terminal, which are preferably selected from Leu, Ala, Cys or Trp. For example, Ser 4 may be replaced by Cys and

simultaneously an additional Cys may be added at the N-terminus. In particular, the single mutant Cys 1 or -1, which contains a free -SH group, may represent an optimal substrate for further chemical modifications.

5 According to other aspects, the invention provides wild-type RANTES, having no internal amino acid mutations but bearing an additional amino acid at the N-terminus, which is preferably Cys, said RANTES derivatives being endowed with anti-HIV and anti-inflammatory activity, and the use of wild-type RANTES added with a
10 Leu at the N-terminus (Leu(0) RANTES) as anti-HIV agent.

It is possible that the properties of some mutants according to the invention, in particular those carrying 1 or 2 additional Cys, are determined by structural modifications due to the formation of a new disulphide bond. Considering the structure of RANTES (Biochem. 1995,
15 34:9307-9314) or the structure of homologous molecules like SDF-1 (EMBO J., 16:6996:7007, 1997), it is also possible that the N-terminal or N-loop regions contribute to form the three-dimensional site of interaction with the specific membrane receptor.

According to another aspect, the invention provides for peptides
20 corresponding to RANTES fragments in the N-terminal, N-loop and/or "40's-loop" regions, said peptides contain the described mutations and competitively antagonise wild-type RANTES, MIP-1 α or MIP-1 β , or the interaction between HIV virus and a chemokine receptor.

According to other aspects, the invention provides nucleotide
25 sequences encoding for the described mutants, the expression vectors comprising such nucleotide sequences, chimeric or fusion proteins which comprise a sequence corresponding to the invention mutants and a carrier

sequence, for example a sequence aimed at improving the pharmacokinetic properties of active peptides or proteins; furthermore, the invention provides the use of such RANTES mutants as anti-HIV agents as well as anti-inflammatory, anti-allergic or anti-asthmatic agents.

5 By the term RANTES, any polypeptide functionally equivalent to the human RANTES is meant, as well as equivalent proteins derived from cross-reactive species, as well as variants and allelic forms thereof which may differ from the standard sequence reported in J. Immunol. 141:1018-1025, 1988.

10 The mutants of the invention may be prepared by conventional techniques of DNA cloning, recombination and in vitro expression, using suitable synthetic oligonucleotides, for example with techniques of site-directed mutagenesis or by the DNA Polymerase Chain Reaction (PCR). The resulting DNA is then inserted into an appropriate expression vector
15 for a prokaryotic or an eukaryotic host. Alternatively, mutants can be prepared according to conventional methods of peptide synthesis.

For the envisaged therapeutical purposes, the mutants of the invention will be administered in form of suitable pharmaceutical compositions by the parenteral, sublingual, intranasal, inhalatory or
20 topical route of administration, prepared according to conventional techniques, which are suitable for polypeptide or protein active substances.

The amount of polypeptide to administer will be sufficient to cause a significant inhibition of HIV infection or replication, or reduction of
25 inflammatory responses, such as in rheumatoid arthritis, or in degenerative diseases such as atherosclerosis, or in allergic diseases such as asthma, rhinitis and dermatitis. The specific dosage will be determined

on the basis of clinical trials and will depend on a number of factors, such as conditions, sex, age and weight of the patient and severity of the condition. The mutants of the invention will be also used in the prevention of HIV infection in individuals potentially exposed to the
5 infection.

Furthermore, the DNA encoding such mutants, which are produced as recombinant proteins in eukaryotic hosts and do not require further chemical modification, may be inserted into gene-therapy vectors (derived for instance, from mouse or human retroviruses, like MuLV or HIV, or
10 Herpes-virus, like HHV-7, or Adenovirus) which allow their production directly into the tissue where the treatment is needed (i.e. lymphonodes, joints, etc.).

The following examples illustrate the invention in more detail.

Example 1:

15 **Cloning and mutagenesis of the RANTES sequence**

Total RNA was extracted according to conventional techniques (Maniatis) from CD8+ T human lymphocytes purified by absorption with the anti CD8 antibody (Sigma C7423) bound to magnetic beads. The cDNA resulting from reverse transcription, using an oligo-dT as primer,
20 was used for a PCR reaction (Polymerase Chain Reaction) with 2 oligonucleotide primers capable of amplifying the whole region coding for RANTES (434 bp):

P1 = 5'- ACGAATTCACAGGTACCATGAAGGTCTCCGCG;

P2 = 5'- GTGGATCCTTTTTGTAAGTCTGCTCGTCGTGGT

25 Primers were designed so as to contain the restriction sites underlined in the P1 and P2 sequences, EcoRI (P1) at 5' and BamHI (P2) at 3', respectively. After amplification, the PCR product was digested

with the EcoRI and BamHI restriction enzymes, purified from the gel by a QIAEX (Promega) column and re-ligated to the pUC18 vector DNA (Promega), digested in the polylinker with the same enzymes.

The religated DNA was then used to transform *E. coli* competent cells (JM109). After selection of some ampicillin resistant clones, the DNA was sequenced to confirm the identity of the insert. Plasmid DNA was used for PCR mutagenesis, according to the procedure called "overlap extension" (Gene, 1991, 67:70). Such a technique allowed the production of single and multiple mutations in the same gene, by the use of common primers (which anneal to the sequence of the vector: A, B, C) and a series of primers specific for the various mutations. The sequences of the common primers are as follows:

primer A: 5'- CAATATGTTGCCGGCATAGTACGCAGC

primer B: 5'- GGATCAGATTTGCAGCGGCCG

15 primer C: 5'- GTGGATCCTTTTTGTAAGTCTGCTCGTCGTGGT

For the construction of pVU5 plasmid, the specific oligo Cys1 was used (5'- GGGTGTGGTGTCCGAGGAATATGGGCAGGCAG). Such primer contains a single base mutation (C instead of G), which determines the substitution of Ser with Cys in position 1.

20 The specific oligo Tyr3 was used for the construction of pVU14 plasmid (5'- GTCCGAGGAAGCTTGGGGAGGCAGATG). Such primer introduces a two bases substitution (GC instead of TA), which determines the substitution of Tyr with Ala in position 3.

The oligo Cys1-Cys5 was used for the construction of pVU15
25 plasmid (5'-GGGTGTGGTGTCGCAGGAATATGGGCAGGCAG), which incorporates a two base substitution (GC instead of CG), in addition to the substitution of primer cys1 (C instead of G). This determines the double

substitution of Ser with Cys in positions 1 and 5.

The specific oligo Arg17

(5' CACGGGGCAGTGGGGCGGCAATGTAG-GCAAAGC)

was used for the construction of pVU24 plasmid. Such primer produces
5 two base substitutions (GC instead of CG) which determine the
substitution of Arg with Ala in position 17.

The specific oligo Asp6

(5'-CAGGGTGTGTGGTCGCGAGGAATATGGGGA)

was used for the construction of pVU38 plasmid. Such primer produces
10 two base substitutions (CG instead of TG) which determine the
substitution of Asp with Arg in position 6.

The specific oligo Arg44

(5'-GGCGGTTCTTTTTCGGTGACAAAGACGAC)

was used for the construction of pVU26 plasmid. Such primer produces a
15 two base substitutions (TC instead of CG) determining the substitution of
Arg 44 with Glu. A second mutant for this position (Arg44—Ala) was
produced with a new oligo having the same sequence except for the
double underlined T, substituted in G.

The specific oligo Lys45

20 (5'-CTTGGCGGTTCTCGGGTGACAAAGACG)

was used for the construction of pVU43 plasmid. Such primer produces a
single base substitution (C instead of T, underlined) which determines the
substitution of Lys with Glu in position 45. A second mutant for this
position (Lys 45—Ala) was produced with a new oligo having the same
25 sequence except for the double underlined T, substituted in G.

The specific oligo Leu-R was used for pVU17 mutant preparation

(5'- ATATGGGGATAAGGCAGATGCAGGAGCGCA). In this primer a

three nucleotides insertion at the 5' of the molecule is added, before the first naturally occurring codon. The antisense triplet encodes for the additional N-terminal Leucine.

The specific oligo Tyr14

5 (5'-TGGGCGGGCAATGGCGGCAAAGCAGCAGGG)

was used for the construction of pVU22 plasmid. Such primer introduce the substitution of Tyr14 with Phe in position 14. A second mutant for this position (Tyr 14-Ala) was also produced.

Other mutants were prepared using the following oligo:

10 Oligo Cys1-Cys4:

5'-GGGTGTGGTGTCCGAGCAATATGGGCAGGCAG;

the substitution of two G with two C (underlined) produces the substitution of two Ser (in positions 1 and 4) with two Cys;

Oligo Cys0-Cys4:

15 CCGAGCAATATGGGGAGGCAGGCAGATGCAGGAG;

the substitution of G with C (underlined) produces the substitution of Ser (in position 4) with Cys, whereas the insertion of GCA produces the insertion of an additional Cys in position 0;

Oligo Leu-Ala:

20 5'-ATATGGGGAGGGCTAAGGCAGATGCAGGA;

the insertion of 6 nucleotides (GGCTAA) upstream the codon of Ser 1 produces the insertion of Leu and Ala in positions -1 and 0, respectively.

Oligo Tyr 14:

5'-TGGGCGGGCAATGTAGGCAAAGCAGCAGGG;

25 the substitution of A in T (underlined) allows the substitution of Tyr14 in Phe.

The PCR products were purified and cloned into the BGIII-BamHI

site of the pUC18 vector. The recombinants were sequenced to confirm their identity and check for undesired mutations introduced during the cloning procedures.

Example 2

5 Expression and purification of the recombinant molecules in Baculovirus

The Baculovirus expression system has been known for some years. It is based on the expression machinery of the *Autographa californica* Nuclear Polyhedrosis Virus (AcNPV). In this system the gene of interest
10 are placed, by homologous recombination, under the control of the polyhedrin gene promoter, which is a non-essential gene but expressed at very high levels during the late phase of viral infection.

The choice of such a system involves a number of advantages, the main ones being: 1) high expression levels; 2) functionality of the
15 recombinant protein, which is correctly processed and folded (most modifications correspond to the ones introduced by mammalian cells); 3) extracellular secretion due to the signal peptide (O'Reilly DR, Miller LK, Luckow VA, "Baculovirus expression vectors - A laboratory manual", Oxford University Press, 1994).

20 In order to express RANTES and its mutants in this system, the corresponding DNA were cut out from pUC18 and cloned into the BamHI-EcoRI site of pVL1392 plasmid polylinker region (Pharmingen), under the control of the polyhedrin promoter. This plasmid also contains downstream of the cloned insert, an AcNPV homology region for
25 homology recombination. An *Autographa californica* continuous cell line (SF9, Pharmingen) was transfected, using the calcium-phosphate co-precipitation, with the DNA of the recombinant plasmids and with the

Baculovirus DNA containing a lethal deletion (BaculoGoldTM DNA, Pharmingen). Only a homologous recombination leading to the substitution of the polyhedrin gene with the DNA of the interesting mutants provides vital viral particles (Gruenwald S, Heitz J, "Baculovirus expression vectors: procedures and methods manual", Pharmingen, 1993).
5 The supernatant of the transfected cultures was then collected at the 3rd day, diluted and used to infect new SF9 cultures, thereby obtaining the viral lineage from a single infectious particles (end-point dilution). As expected, the RANTES protein and its mutants are secreted and their
10 expression levels may be evaluated by a commercial ELISA test (R&D). The viral DNA was extracted from the potential recombinants, as detected by ELISA, and sequenced by PCR (Cycle Sequencing, Amersham) to confirm that the mutations had also occurred in the viral lineage. The selected viral stock was subsequently subjected to repeated cycles of
15 infection and amplification in SF9 cells, to obtain high titer supernatants. These supernatants were used for the production of recombinant chemokines on a large scale, infecting a continuous Trichoplusia cell line (High Five, Invitrogen). These cells are capable of growth in a serum-free medium, simplifying the following protein purification procedures.
20 1.5×10^8 cells were infected with 1.5×10^9 vital viral particles in a final volume of 200 ml. At the 4th infection day the supernatant was collected, filtered (0.45 μ) and the mutants purified on heparin columns. After repeated washing with PBS, the column was eluted with PBS + 1.5 M NaCl in 10 ml. An aliquot of the eluate was subjected to electrophoresis
25 on acrylamide gel SDS-PAGE and stained with Coomassie blue, thus evaluating a 90% purity of the recombinant proteins. The eluate was subsequently dia-filtered to remove the present salts and concentrated

(Centricon, cut-off 3000, Millipore). The final quantification of RANTES and its mutants was performed by an ELISA kit for the quantitative determination of RANTES (R&D) and confirmed by Western blot and capillary electrophoresis.

5 **Example 3**

Inhibition of viral infection

The ability of the mutants obtained as in Example 2, to inhibit infection by the prototypic macrophage-tropic viral strain, HIV-1BaL, was measured in primary cultures of activated peripheral blood mononuclear cells (PMBC). The procedure used to infect PBL and to evaluate p24 antigen production has been already described in the literature (Scarlati et al., Nature Medicine, 1997). The dose inhibiting viral proliferation by 90% (ID90) was remarkably lower for pVU15 as compared to wild-type RANTES which has an ID90 of 96 ng/ml (figure 1). The suppressive activity of pVU5, pVU14, pVU15, pVU24 and pVU38, was confirmed in another HIV strain, isolated from a patient with asymptomatic infection (HIV-1 6366) and passaged only once in peripheral blood mononuclear cells (figure 2): as for the BaL strain, this isolate depended upon CCR5 co-receptor usage(ibid.). The antiviral activity of the polypeptides of the invention, expressed as relative potency with respect to wild-type RANTES (ID90 RANTES/ID90 mutant) is illustrated in the following table.

10

15

20

Table: Relative antiviral activity of RANTES mutants (fold increase compared to wild -type RANTES)

Derivatives	Mutations	PBMC		MDM
		HIV-1BaL	HIV-1 6366	HIV-1BaL
PVU 5	S1 → C	0.24	0.23	0.25
PVU 14	Y3 → A	0.22	0.10	0.23
PVU 15	S1 → C	3.07	3.3	4.5
	S5 → C			
PVU24	R17 → A	1.09	1.30	Nt
PVU38	D6 → R	0.14	0.13	Nt
PVU26*	R44 → E	3.16	Nt	Nt
PVU43*	K45 → E	1.44	Nt	Nt
<u>PVU22</u>	Y14 → F	10.0	2.5	Nt
<u>PVU17</u>	L added	4.6	1.9	11.0

- 5 *The antiviral activity of pVU26 and pVU43 mutants is expressed as relative potency with respect to wild-type RANTES (RANTES ID50/mutant ID 50).

Example 4

Pro-inflammatory activity

- 10 The ability of the RANTES mutants to mobilise intra-cellular calcium, which is induced by G-protein-coupled receptor activation and it is connected to the efficacy of signal trasduction of various ligands, was studied.

- Cells were loaded with Fura-2 for one hour and stimulated by
15 mutants at different concentrations. The effect was measured using a

fluorimeter and calculated as the % increase of intra-cellular calcium. Wild-type RANTES induced a dose-dependent calcium mobilisation in U87-CD4 cells expressing CCR5 but not in CCR5-negative cells used as the control. Among pVU5, pVU14, pVU15, pVU24, pVU38, pVU26 and
5 pVU43 tested mutants, only pVU38 pVU15 and pVU17 did not induce calcium mobilisation. pVU5, pVU14 and pVU43 had an efficacy lower than wild-type RANTES, as shown in figure 3.

The ability of the polypeptides of the invention to induce chemotaxis of primary human lymphocytes and monocytes was also
10 measured, which ability can be mediated by different RANTES receptors, especially by CCR1.

Monocyte migration was assayed using a modification of the Boyden chamber (48 well Transwell(TM), Costar). After 2 hours incubation in the presence of mutants at various concentrations, the filter
15 was removed and migrated cells counted with a FACS. The chemotactic index represents the ratio of the number of cells that migrated in the presence of mutants to that due to the spontaneous migration. All the mutants except pVU5 and pVU14, induced monocyte chemotaxis, but at high concentrations, ranging from 100 to 500 ng/ml, pVU38 mutant
20 exhibited an efficacy clearly lower than wild-type RANTES (figure 4).

Thus, whereas the ratio of the minimal chemotactic dose to the 90% HIV-suppressive dose in PBMC was between 8 and 50 for the mutant, it was between 1.0 and 2.9 for wild-type RANTES.

Example 5

25 RANTES antagonistic effect

The ability of the mutant pVU15 and pVU17 to antagonise CCR3- and CCR5- receptor activation by wild-type RANTES, was studied in

terms of intracellular calcium mobilisation.

When added immediately prior to the wild-type molecule, pVU15 reduced the response to wild-type RANTES with a dose-dependent effect. With respect to CCR5, a concentration of 500 ng/ml gave the highest
5 inhibition of wild-type RANTES activity, while with respect to CCR3, the receptor desensitisation was incomplete (see figures 5 and 6).

The fluorescence signal, induced by changes in intra-cellular Ca^{++} , was monitored with a fluorometer.

CLAIMS

1. A RANTES mutant wherein, as compared to human wild-type RANTES, at least one amino acid is mutated in the N-terminal region, in
5 the N-loop region, in the 40's-loop region or in all the three regions, said mutant having the capability to competitively antagonise wild type RANTES, MIP-1 α or MIP-1 β , or to antagonise the interaction between HIV virus and a chemokine receptor.
2. A RANTES mutant according to claim 1, wherein one or more of
10 the following amino acids is/are mutated: Ser 1, Tyr 3, Ser 4, Ser 5, Asp 6, Tyr 14 Arg 17, Arg 44, Lys 45,.
3. A RANTES mutant according to claim 2, wherein the mutation is selected from:
 - a) Ser 1 with a neutral or hydrophobic amino acid;
 - 15 b) Ser 4 with a neutral or hydrophobic amino acid;
 - c) Ser 5 with a neutral or hydrophobic amino acid;
 - d) Tyr 3 with a neutral or hydrophobic amino acid;
 - e) Asp 6 with a positively charged amino acid;
 - f) Tyr 14 with a idrophobic aromatic amino acid;
 - 20 g) Arg 17 with a small-sized hydrophobic amino acid;
 - h) Arg 44 with a negatively charged or a small hydrophobic amino acid;
 - i) Lys 45 with a negatively charged or a small hydrophobic amino acid;.
- 25 4. A RANTES mutant according to claim 3, wherein said mutation is selected from:
 - a) Ser 1 with Cys;

- b) Ser 4 with Cys;
 - c) Ser 5 with Cys;
 - d) Tyr 3 with Ala;
 - e) Tyr 14 with Phe;
 - 5 f) Asp 6 with Arg;
 - g) Arg 17 with Ala;
 - h) Arg 44 with Glu or Ala;
 - i) Arg 45 with Glu or Ala;
5. A RANTES mutant according to claim 4, comprising a triple
- 10 mutation selected from :
- a) Ser 1 with Cys; Ser 5 with Cys; Asp 6 with Arg;
 - b) Ser 1 with Cys; Ser 5 with Cys; Arg 17 with Ala;
 - c) Ser 1 with Cys; Ser 5 with Cys; Arg 44 with Glu or Ala;
6. A RANTES mutant according to claim 4, comprising a double
- 15 mutation selected from:
- a) Ser 1 with Cys; Ser 5 with Cys;
 - b) Ser 1 with Cys; Ser 4 with Cys;
 - c) Ser 1 with Cys; Arg 44 with Glu or Ala;
 - d) Asp 6 with Arg; Arg 44 with Glu or Ala;
- 20 7. A RANTES mutant according to claim 4, comprising a single mutation selected from:
- a) Tyr 3 with Ala;
 - b) Ser 1 with Cys;
 - c) Asp 6 with Arg;
 - 25 d) Tyr 14 with Phe
 - e) Arg 17 with Ala;
 - f) Arg 44 with Glu or Ala;

g) Lys 45 with Glu or Ala.

8. A RANTES mutant according to anyone of the preceding claims, further comprising one or two additional amino acids at the N-terminal.
9. A RANTES mutant according to claim 8, wherein said additional
5 amino acids are selected from Leu, Ala, Cys, and Trp.
10. A RANTES mutant according to claim 9, wherein said additional amino acid is Leu.
11. A RANTES mutant according to claims 8-9, wherein Cys is added at the N-terminal and Ser 4 is mutated into Cys.
- 10 12. A RANTES mutant according to claims 8-9, wherein Cys is added at the N-terminal and Ser 5 is mutated into Cys.
13. A peptide derived from RANTES sequence of N-terminal, N-loop or 40's loop regions comprising the mutation or addition of claims 1-11, having the ability to competitively antagonise wild type RANTES, MIP-
15 1 α or MIP-1 β , or to antagonise the interaction between HIV virus and a chemokine receptor.
14. Wild-type RANTES added with an amino acid at the N-terminus, wherein said amino acid is Cys.
15. A nucleotide sequence encoding a RANTES mutant of claims
20 1-12.
16. A vector for eukaryotic or prokaryotic expression comprising the sequence of claim 15.
17. A pharmaceutical composition having HIV-inhibiting, antiallergic, antiasthmatic or anti-inflammatory activity, comprising a mutant of
25 claims 1-12 or the RANTES derivative of claim 14 as the active ingredient.
18. A pharmaceutical composition having HIV-inhibiting, antiallergic,

antiasthmatic or anti-inflammatory activity, comprising a peptide of claim 13 as the active ingredient.

19. A process for preparing RANTES mutants of claims 1-12 which comprises culturing eukaryotic cells trasfected with vectors containing
5 DNA fragments encoding said mutants.

20. A process according to claim 19, wherein said vector is a baculovirus expression vector.

21. A process according to claim 19, wherein said vector is a E. coli expression vector.

10 22. The use of wild-type RANTES added with a residue of Leu at the N-terminus (Leu(0) RANTES), for the preparation of a medicament having anti-HIV activity.

FIGURE 3






FIGURE 4




Desensitization of the receptors by pVU15

FIGURE 5



Desensitization of the receptors by pVU17

FIGURE 6



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/19, C07K 14/52, A61K 38/19, C12N 5/10, 1/21		A2	(11) International Publication Number: WO 99/33989 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/EP98/08354 (22) International Filing Date: 21 December 1998 (21.12.98) (30) Priority Data: MI97A002865 23 December 1997 (23.12.97) IT MI98A001866 7 August 1998 (07.08.98) IT (71) Applicant (for all designated States except US): FON- DAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): LUSSO, Paolo [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). POLO, Simona [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: RANTES MUTANTS AND THERAPEUTIC APPLICATIONS THEREOF			
(57) Abstract RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

RANTES MUTANTS AND THERAPEUTIC APPLICATIONS THEREOF

The present invention provides RANTES mutants with reduced pro-inflammatory activity, increased HIV-suppressive activity, and antagonistic activity to wild-type chemokines.

Chemokines are small proteins involved in inflammatory mechanisms and in physiologic circulation of hemopoietic cells. Several studies have shown the important role of chemokines in recruiting leucocytes in inflammatory and autoimmune diseases, like rheumatoid arthritis, or during allergic reactions, like in asthma (Schall, T.J. The chemokines. In: The cytokine handbook, A Thompson ed. Academic Press, New York, 1994, p.419-460). Furthermore, some chemokines have been recently identified as potent natural inhibitors of human immunodeficiency virus (HIV) infection (Science 270, 1811-1815, 1995). Chemokines activity is due to their interaction with receptors having different specificity and expressed on the cell surface. Some of these receptors function as co-receptors for HIV-virus (Science 272, 872-877, 1996; Science 272, 1955-1958, 1996). The differential use of such co-receptors, particularly CCR5 the specific receptor for RANTES, MIP-1 α and MIP-1 β , and CXCR4, the SDF-1 specific receptor, represents a major determinant of the biological diversity among HIV strains. HIV-1 strains unable to infect continuous CD4+ T-cell lines, commonly involved in viral transmission and predominating during the asymptomatic phase of the infection, use primarily CCR5 as a co-receptor and are invariably sensitive to inhibition by CCR5-binding chemokines (Nature Med., 3:1259-1265, 1997). The most effective such chemokine, RANTES, is

therefore under investigation for the development of novel anti-HIV therapies (Nature, 383: 400, 1996). RANTES is a chemokine which belongs to the C-C family and is 68 amino acids long. Its sequence has been reported in J. Immunol. (1988).

5 WO 96/17935 discloses RANTES molecules which are modified at the N-terminus through the addition of an amino acid such as methionine, leucine or glutamine, as antagonists of RANTES or MIP-1 α . In particular, the use thereof for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma-atherosclerosis or rheumatoid arthritis is described.

10 Further, Elsner J. et al.. in "European Journal of Immunology, Vol. 27, 2892-2898 (1997)", and WO 96/17934, disclose the antagonistic activity of the Met-RANTES peptide.

The use of wild-type RANTES and of other chemokines of the same family in the treatment of allergic diseases, has been also described
15 in WO 94/07521 and WO 94/21277.

WO 97/25350 discloses disaggregated mutants of MIP-1 α or LD78 having HIV suppressive activity, whereas WO 98/13495 discloses human RANTES mutants unable to aggregate under physiologic ionic strength and which exhibit antiviral activity. Surprisingly now, it has been found
20 that the addition of at least one amino acid at the N-terminus, and/or the substitution of one or more amino acids in the N-terminal region comprised between amino acids 1 and 11 of the mature form of the human chemokine RANTES, and/or in the "40's-loop" region, extending from Thr 43 to Asn 46, provides a notably higher efficacy towards different
25 HIV isolates, both in primary mononucleated blood cells and in macrophages, a reduced pro-inflammatory activity and a potent antagonistic activity, as compared to the wild-type molecule. In

particular, the mutants of the invention competitively antagonise wild-type RANTES, MIP-1 α or MIP-1 β , and, with a comparable mechanism, the interaction between the HIV virus and a chemokine receptor. Preferably, one or more of the amino acids: Ser 1, Ser 4, Ser 5, Tyr 3, Asp 6, Tyr 14, Arg 17, Arg 44, Lys 33, Lys 45 and Arg 46 are mutated, with respect to the wild-type human form described in J. Immunol. 141:1018-1025, 1988, as reference molecule. Preferably, the amino acids Ser 1, Ser 4, Ser 5, Tyr 3 are replaced by neutral or hydrophobic amino acids, Asp 6 is replaced by a positively charged amino acid, Tyr 14 by a hydrophobic aromatic, Arg 17, Lys 33, Arg 44, Lys 45 and Arg 46 by a small sized hydrophobic amino acid.

The following mutations are more preferred: Ser 1 with Cys, Ser 4 with Cys, Ser 5 with Cys, Tyr 3 with Ala, Asp 6 with Arg, Tyr 14 with Phe, Arg 17, Lys 33, Arg 44, Lys 45 and Arg 46 with Ala. A first group of mutants according to the invention is characterised by a triple mutation selected from a) Ser 1 with Cys; Ser 5 with Cys; Asp 6 with Arg, or b) Ser 1 with Cys; Ser 5 with Cys; Arg 17 with Ala, or c) Ser 1 with Cys; Ser 5 with Cys; Arg 44 or Lys 45 or Arg 46, with Ala. A second group is characterised by a double mutation selected from a) Ser 1 and Ser 5 with Cys, or b) Ser 1 and Ser 4 with Cys, or c) Ser 1 with Cys and Arg 44 with Ala, or d) Asp 6 with Arg and Arg 44 with Ala. A third group is characterised by a single mutation selected from a) Ser 1 with Cys, b) Tyr 3 with Ala, c) Asp 6 with Arg, d) Tyr 14 with Phe, e) Arg 17 with Ala, f) Lys 33 with Ala, g) Arg 44 with Ala, h) Lys 45 with Ala, i) Arg 46 with Ala. Furthermore, the above mutants can be added with up to two amino acids at the N-terminal, which are preferably selected from Leu, Ala, Cys or Trp. For example, Ser 4 may be replaced by Cys and

simultaneously an additional Cys may be added at the N-terminus. In particular, the single mutant Cys 1 or -1, which contains a free -SH group, may represent an optimal substrate for further chemical modifications.

5 According to other aspects, the invention provides wild-type RANTES, having no internal amino acid mutations but bearing an additional amino acid at the N-terminus, which is preferably Cys, said RANTES derivatives being endowed with anti-HIV and anti-inflammatory activity, and the use of wild-type RANTES added with a
10 Leu at the N-terminus (Leu(0) RANTES) as anti-HIV agent.

It is possible that the properties of some mutants according to the invention, in particular those carrying 1 or 2 additional Cys, are determined by structural modifications due to the formation of a new disulphide bond. Considering the structure of RANTES (Biochem. 1995,
15 34:9307-9314) or the structure of homologous molecules like SDF-1 (EMBO J., 16:6996:7007, 1997), it is also possible that the N-terminal or N-loop regions contribute to form the three-dimensional site of interaction with the specific membrane receptor.

According to another aspect, the invention provides for peptides
20 corresponding to RANTES fragments in the N-terminal, N-loop and/or "40's-loop" regions, said peptides contain the described mutations and competitively antagonise wild-type RANTES, MIP-1 α or MIP-1 β , or the interaction between HIV virus and a chemokine receptor.

According to other aspects, the invention provides nucleotide
25 sequences encoding for the described mutants, the expression vectors comprising such nucleotide sequences, chimeric or fusion proteins which comprise a sequence corresponding to the invention mutants and a carrier

sequence, for example a sequence aimed at improving the pharmacokinetic properties of active peptides or proteins; furthermore, the invention provides the use of such RANTES mutants as anti-HIV agents as well as anti-inflammatory, anti-allergic or anti-asthmatic agents.

5 By the term RANTES, any polypeptide functionally equivalent to the human RANTES is meant, as well as equivalent proteins derived from cross-reactive species, as well as variants and allelic forms thereof which may differ from the standard sequence reported in J. Immunol. 141:1018-1025, 1988.

10 The mutants of the invention may be prepared by conventional techniques of DNA cloning, recombination and in vitro expression, using suitable synthetic oligonucleotides, for example with techniques of site-directed mutagenesis or by the DNA Polymerase Chain Reaction (PCR). The resulting DNA is then inserted into an appropriate expression vector
15 for a prokaryotic or an eukaryotic host. Alternatively, mutants can be prepared according to conventional methods of peptide synthesis.

For the envisaged therapeutical purposes, the mutants of the invention will be administered in form of suitable pharmaceutical compositions by the parenteral, sublingual, intranasal, inhalatory or
20 topical route of administration, prepared according to conventional techniques, which are suitable for polypeptide or protein active substances.

The amount of polypeptide to administer will be sufficient to cause a significant inhibition of HIV infection or replication, or reduction of
25 inflammatory responses, such as in rheumatoid arthritis, or in degenerative diseases such as atherosclerosis, or in allergic diseases such as asthma, rhinitis and dermatitis. The specific dosage will be determined

on the basis of clinical trials and will depend on a number of factors, such as conditions, sex, age and weight of the patient and severity of the condition. The mutants of the invention will be also used in the prevention of HIV infection in individuals potentially exposed to the
5 infection.

Furthermore, the DNA encoding such mutants, which are produced as recombinant proteins in eukaryotic hosts and do not require further chemical modification, may be inserted into gene-therapy vectors (derived for instance, from mouse or human retroviruses, like MuLV or HIV, or
10 Herpes-virus, like HHV-7, or Adenovirus) which allow their production directly into the tissue where the treatment is needed (i.e. lymphonodes, joints, etc.).

The following examples illustrate the invention in more detail.

Example 1:

15 **Cloning and mutagenesis of the RANTES sequence**

Total RNA was extracted according to conventional techniques (Maniatis) from CD8+ T human lymphocytes purified by absorption with the anti CD8 antibody (Sigma C7423) bound to magnetic beads. The cDNA resulting from reverse transcription, using an oligo-dT as primer,
20 was used for a PCR reaction (Polymerase Chain Reaction) with 2 oligonucleotide primers capable of amplifying the whole region coding for RANTES (434 bp):

P1 = 5'- ACGAATTCACAGGTACCATGAAGGTCTCCGCG;

P2 = 5'- GTGGATCCTTTTTGTAAGTCTGCTCGTCGTGGT

25 Primers were designed so as to contain the restriction sites underlined in the P1 and P2 sequences, EcoRI (P1) at 5' and BamHI (P2) at 3', respectively. After amplification, the PCR product was digested

with the EcoRI and BamHI restriction enzymes, purified from the gel by a QIAEX (Promega) column and re-ligated to the pUC18 vector DNA (Promega), digested in the polylinker with the same enzymes.

The religated DNA was then used to transform *E. coli* competent cells (JM109). After selection of some ampicillin resistant clones, the DNA was sequenced to confirm the identity of the insert. Plasmid DNA was used for PCR mutagenesis, according to the procedure called "overlap extension" (Gene, 1991, 67:70). Such a technique allowed the production of single and multiple mutations in the same gene, by the use of common primers (which anneal to the sequence of the vector: A, B, C) and a series of primers specific for the various mutations. The sequences of the common primers are as follows:

primer A: 5'- CAATATGTTGCCGGCATAGTACGCAGC

primer B: 5'- GGATCAGATTTGCAGCGGCCG

15 primer C: 5'- GTGGATCCTTTTTGTAAGTCTGCTCGTCGTGGT

For the construction of pVU5 plasmid, the specific oligo Cys1 was used (5'- GGGTGTGGTGTCCGAGGAATATGGGCAGGCAG). Such primer contains a single base mutation (C instead of G), which determines the substitution of Ser with Cys in position 1.

20 The specific oligo Tyr3 was used for the construction of pVU14 plasmid (5'- GTCCGAGGAAGCTGGGGAGGCAGATG). Such primer introduces a two bases substitution (GC instead of TA), which determines the substitution of Tyr with Ala in position 3.

The oligo Cys1-Cys5 was used for the construction of pVU15 plasmid (5'-GGGTGTGGTGTCCGCAGGAATATGGGCAGGCAG), which incorporates a two base substitution (GC instead of CG), in addition to the substitution of primer cys1 (C instead of G). This determines the double

substitution of Ser with Cys in positions 1 and 5.

The specific oligo Arg17

(5' CACGGGGCAGTGGGGCGGCAATGTAG-GCAAAGC)

was used for the construction of pVU24 plasmid. Such primer produces
5 two base substitutions (GC instead of CG) which determine the
substitution of Arg with Ala in position 17.

The specific oligo Asp6

(5'-CAGGGTGTGTGGTGCGGAGGAATATGGGGA)

was used for the construction of pVU38 plasmid. Such primer produces
10 two base substitutions (CG instead of TG) which determine the
substitution of Asp with Arg in position 6.

The specific oligo Arg44

(5'-GGCGGTTCTTTTCGGTGACAAAGACGAC)

was used for the construction of pVU26 plasmid. Such primer produces a
15 two base substitutions (TC instead of CG) determining the substitution of
Arg 44 with Glu. A second mutant for this position (Arg44—Ala) was
produced with a new oligo having the same sequence except for the
double underlined T, substituted in G.

The specific oligo Lys45

20 (5'-CTTGGCGGTTCTCTCGGGTGACAAAGACG)

was used for the construction of pVU43 plasmid. Such primer produces a
single base substitution (C instead of T, underlined) which determines the
substitution of Lys with Glu in position 45. A second mutant for this
position (Lys 45—Ala) was produced with a new oligo having the same
25 sequence except for the double underlined T, substituted in G.

The specific oligo Leu-R was used for pVU17 mutant preparation

(5'- ATATGGGGATAAAGGCAGATGCAGGAGCGCA). In this primer a

three nucleotides insertion at the 5' of the molecule is added, before the first naturally occurring codon. The antisense triplet encodes for the additional N-terminal Leucine.

The specific oligo Tyr14

5 (5'-TGGGCGGGCAATGGCGGCAAAGCAGCAGGG)

was used for the construction of pVU22 plasmid. Such primer introduce the substitution of Tyr14 with Phe in position 14. A second mutant for this position (Tyr 14-Ala) was also produced.

Other mutants were prepared using the following oligo:

10 Oligo Cys1-Cys4:

5'-GGGTGTGGTGTCCGAGCAATATGGGCAGGCAG;

the substitution of two G with two C (underlined) produces the substitution of two Ser (in positions 1 and 4) with two Cys;

Oligo Cys0-Cys4:

15 CCGAGCAATATGGGGAGCAGGCAGATGCAGGAG;

the substitution of G with C (underlined) produces the substitution of Ser (in position 4) with Cys, whereas the insertion of GCA produces the insertion of an additional Cys in position 0;

Oligo Leu-Ala:

20 5'-ATATGGGGAGGCTAAAGGCAGATGCAGGA;

the insertion of 6 nucleotides (GGCTAA) upstream the codon of Ser 1 produces the insertion of Leu and Ala in positions -1 and 0, respectively.

Oligo Tyr 14:

5'-TGGGCGGGCAATGTAGGCAAAGCAGCAGGG;

25 the substitution of A in T (underlined) allows the substitution of Tyr14 in Phe.

The PCR products were purified and cloned into the BGIII-BamHI

site of the pUC18 vector. The recombinants were sequenced to confirm their identity and check for undesired mutations introduced during the cloning procedures.

Example 2

5 Expression and purification of the recombinant molecules in Baculovirus

The Baculovirus expression system has been known for some years. It is based on the expression machinery of the *Autographa californica* Nuclear Polyhedrosis Virus (AcNPV). In this system the gene of interest
10 are placed, by homologous recombination, under the control of the polyhedrin gene promoter, which is a non-essential gene but expressed at very high levels during the late phase of viral infection.

The choice of such a system involves a number of advantages, the main ones being: 1) high expression levels; 2) functionality of the
15 recombinant protein, which is correctly processed and folded (most modifications correspond to the ones introduced by mammalian cells); 3) extracellular secretion due to the signal peptide (O'Reilly DR, Miller LK, Luckow VA, "Baculovirus expression vectors - A laboratory manual", Oxford University Press, 1994).

20 In order to express RANTES and its mutants in this system, the corresponding DNA were cut out from pUC18 and cloned into the BamHI-EcoRI site of pVL1392 plasmid polylinker region (Pharminogen), under the control of the polyhedrin promoter. This plasmid also contains downstream of the cloned insert, an AcNPV homology region for
25 homology recombination. An *Autographa californica* continuous cell line (SF9, Pharminogen) was transfected, using the calcium-phosphate co-precipitation, with the DNA of the recombinant plasmids and with the

Baculovirus DNA containing a lethal deletion (BaculoGold™ DNA, Pharmingen). Only a homologous recombination leading to the substitution of the polyhedrin gene with the DNA of the interesting mutants provides vital viral particles (Gruenwald S, Heitz J, "Baculovirus expression vectors: procedures and methods manual", Pharmingen, 1993).
5 The supernatant of the transfected cultures was then collected at the 3rd day, diluted and used to infect new SF9 cultures, thereby obtaining the viral lineage from a single infectious particles (end-point dilution). As expected, the RANTES protein and its mutants are secreted and their
10 expression levels may be evaluated by a commercial ELISA test (R&D). The viral DNA was extracted from the potential recombinants, as detected by ELISA, and sequenced by PCR (Cycle Sequencing, Amersham) to confirm that the mutations had also occurred in the viral lineage. The selected viral stock was subsequently subjected to repeated cycles of
15 infection and amplification in SF9 cells, to obtain high titer supernatants. These supernatants were used for the production of recombinant chemokines on a large scale, infecting a continuous Trichoplusia cell line (High Five, Invitrogen). These cells are capable of growth in a serum-free medium, simplifying the following protein purification procedures.
20 1.5×10^8 cells were infected with 1.5×10^9 vital viral particles in a final volume of 200 ml. At the 4th infection day the supernatant was collected, filtered (0.45 μ) and the mutants purified on heparin columns. After repeated washing with PBS, the column was eluted with PBS + 1.5 M NaCl in 10 ml. An aliquot of the eluate was subjected to electrophoresis
25 on acrylamide gel SDS-PAGE and stained with Coomassie blue, thus evaluating a 90% purity of the recombinant proteins. The eluate was subsequently dia-filtered to remove the present salts and concentrated

(Centricon, cut-off 3000, Millipore). The final quantification of RANTES and its mutants was performed by an ELISA kit for the quantitative determination of RANTES (R&D) and confirmed by Western blot and capillary electrophoresis.

5 **Example 3**

Inhibition of viral infection

The ability of the mutants obtained as in Example 2, to inhibit infection by the prototypic macrophage-tropic viral strain, HIV-1BaL, was measured in primary cultures of activated peripheral blood mononuclear cells (PMBC). The procedure used to infect PBL and to evaluate p24 antigen production has been already described in the literature (Scarlati et al., Nature Medicine, 1997). The dose inhibiting viral proliferation by 90% (ID90) was remarkably lower for pVU15 as compared to wild-type RANTES which has an ID90 of 96 ng/ml (figure 1). The suppressive activity of pVU5, pVU14, pVU15, pVU24 and pVU38, was confirmed in another HIV strain, isolated from a patient with asymptomatic infection (HIV-1 6366) and passaged only once in peripheral blood mononuclear cells (figure 2): as for the BaL strain, this isolate depended upon CCR5 co-receptor usage(ibid.). The antiviral activity of the polypeptides of the invention, expressed as relative potency with respect to wild-type RANTES (ID90 RANTES/ID90 mutant) is illustrated in the following table.

10
15
20

Table: Relative antiviral activity of RANTES mutants (fold increase compared to wild -type RANTES)

Derivatives	Mutations	PBMC		MDM
		HIV-1BaL	HIV-1 6366	HIV-1BaL
PVU 5	S1 → C	0.24	0.23	0.25
PVU 14	Y3 → A	0.22	0.10	0.23
PVU 15	S1 → C	3.07	3.3	4.5
	S5 → C			
PVU24	R17 → A	1.09	1.30	Nt
PVU38	D6 → R	0.14	0.13	Nt
PVU26*	R44 → E	3.16	Nt	Nt
PVU43*	K45 → E	1.44	Nt	Nt
PVU22	Y14 → F	10.0	2.5	Nt
PVU17	L added	4.6	1.9	11.0

- 5 *The antiviral activity of pVU26 and pVU43 mutants is expressed as relative potency with respect to wild-type RANTES (RANTES ID50/mutant ID 50).

Example 4

Pro-inflammatory activity

- 10 The ability of the RANTES mutants to mobilise intra-cellular calcium, which is induced by G-protein-coupled receptor activation and it is connected to the efficacy of signal trasduction of various ligands, was studied.

- Cells were loaded with Fura-2 for one hour and stimulated by
15 mutants at different concentrations. The effect was measured using a

fluorimeter and calculated as the % increase of intra-cellular calcium. Wild-type RANTES induced a dose-dependent calcium mobilisation in U87-CD4 cells expressing CCR5 but not in CCR5-negative cells used as the control. Among pVU5, pVU14, pVU15, pVU24, pVU38, pVU26 and
5 pVU43 tested mutants, only pVU38 pVU15 and pVU17 did not induce calcium mobilisation. pVU5, pVU14 and pVU43 had an efficacy lower than wild-type RANTES, as shown in figure 3.

The ability of the polypeptides of the invention to induce chemotaxis of primary human lymphocytes and monocytes was also
10 measured, which ability can be mediated by different RANTES receptors, especially by CCR1.

Monocyte migration was assayed using a modification of the Boyden chamber (48 well Transwell(TM), Costar). After 2 hours incubation in the presence of mutants at various concentrations, the filter
15 was removed and migrated cells counted with a FACS. The chemotactic index represents the ratio of the number of cells that migrated in the presence of mutants to that due to the spontaneous migration. All the mutants except pVU5 and pVU14, induced monocyte chemotaxis, but at high concentrations, ranging from 100 to 500 ng/ml, pVU38 mutant
20 exhibited an efficacy clearly lower than wild-type RANTES (figure 4).

Thus, whereas the ratio of the minimal chemotactic dose to the 90% HIV-suppressive dose in PBMC was between 8 and 50 for the mutant, it was between 1.0 and 2.9 for wild-type RANTES.

Example 5

25 RANTES antagonistic effect

The ability of the mutant pVU15 and pVU17 to antagonise CCR3- and CCR5- receptor activation by wild-type RANTES, was studied in

terms of intracellular calcium mobilisation.

When added immediately prior to the wild-type molecule, pVU15 reduced the response to wild-type RANTES with a dose-dependent effect. With respect to CCR5, a concentration of 500 ng/ml gave the highest
5 inhibition of wild-type RANTES activity, while with respect to CCR3, the receptor desensitisation was incomplete (see figures 5 and 6).

The fluorescence signal, induced by changes in intra-cellular Ca^{++} , was monitored with a fluorometer.

CLAIMS

1. A RANTES mutant wherein, as compared to human wild-type RANTES, at least one amino acid is mutated in the N-terminal region, in
5 the N-loop region, in the 40's-loop region or in all the three regions, said mutant having the capability to competitively antagonise wild type RANTES, MIP-1 α or MIP-1 β , or to antagonise the interaction between HIV virus and a chemokine receptor.
2. A RANTES mutant according to claim 1, wherein one or more of
10 the following amino acids is/are mutated: Ser 1, Tyr 3, Ser 4, Ser 5, Asp 6, Tyr 14 Arg 17, Arg 44, Lys 45,.
3. A RANTES mutant according to claim 2, wherein the mutation is selected from:
 - a) Ser 1 with a neutral or hydrophobic amino acid;
 - 15 b) Ser 4 with a neutral or hydrophobic amino acid;
 - c) Ser 5 with a neutral or hydrophobic amino acid;
 - d) Tyr 3 with a neutral or hydrophobic amino acid;
 - e) Asp 6 with a positively charged amino acid;
 - f) Tyr 14 with a idrophobic aromatic amino acid;
 - 20 g) Arg 17 with a small-sized hydrophobic amino acid;
 - h) Arg 44 with a negatively charged or a small hydrophobic amino acid;
 - i) Lys 45 with a negatively charged or a small hydrophobic amino acid;.
- 25 4. A RANTES mutant according to claim 3, wherein said mutation is selected from:
 - a) Ser 1 with Cys;

- b) Ser 4 with Cys;
 - c) Ser 5 with Cys;
 - d) Tyr 3 with Ala;
 - e) Tyr 14 with Phe;
 - 5 f) Asp 6 with Arg;
 - g) Arg 17 with Ala;
 - h) Arg 44 with Glu or Ala;
 - i) Arg 45 with Glu or Ala;
5. A RANTES mutant according to claim 4, comprising a triple
- 10 mutation selected from :
- a) Ser 1 with Cys; Ser 5 with Cys; Asp 6 with Arg;
 - b) Ser 1 with Cys; Ser 5 with Cys; Arg 17 with Ala;
 - c) Ser 1 with Cys; Ser 5 with Cys; Arg 44 with Glu or Ala;
6. A RANTES mutant according to claim 4, comprising a double
- 15 mutation selected from:
- a) Ser 1 with Cys; Ser 5 with Cys;
 - b) Ser 1 with Cys; Ser 4 with Cys;
 - c) Ser 1 with Cys; Arg 44 with Glu or Ala;
 - d) Asp 6 with Arg; Arg 44 with Glu or Ala;
- 20 7. A RANTES mutant according to claim 4, comprising a single mutation selected from:
- a) Tyr 3 with Ala;
 - b) Ser 1 with Cys;
 - c) Asp 6 with Arg;
 - 25 d) Tyr 14 with Phe
 - e) Arg 17 with Ala;
 - f) Arg 44 with Glu or Ala;

- 18 -

g) Lys 45 with Glu or Ala.

8. A RANTES mutant according to anyone of the preceding claims, further comprising one or two additional amino acids at the N-terminal.
9. A RANTES mutant according to claim 8, wherein said additional
5 amino acids are selected from Leu, Ala, Cys, and Trp.
10. A RANTES mutant according to claim 9, wherein said additional amino acid is Leu.
11. A RANTES mutant according to claims 8-9, wherein Cys is added at the N-terminal and Ser 4 is mutated into Cys.
- 10 12. A RANTES mutant according to claims 8-9, wherein Cys is added at the N-terminal and Ser 5 is mutated into Cys.
13. A peptide derived from RANTES sequence of N-terminal, N-loop or 40's loop regions comprising the mutation or addition of claims 1-11, having the ability to competitively antagonise wild type RANTES, MIP-
15 1 α or MIP-1 β , or to antagonise the interaction between HIV virus and a chemokine receptor.
14. Wild-type RANTES added with an amino acid at the N-terminus, wherein said amino acid is Cys.
15. A nucleotide sequence encoding a RANTES mutant of claims
20 1-12.
16. A vector for eukaryotic or prokaryotic expression comprising the sequence of claim 15.
17. A pharmaceutical composition having HIV-inhibiting, antiallergic, antiasthmatic or anti-inflammatory activity, comprising a mutant of
25 claims 1-12 or the RANTES derivative of claim 14 as the active ingredient.
18. A pharmaceutical composition having HIV-inhibiting, antiallergic,

antiasthmatic or anti-inflammatory activity, comprising a peptide of claim 13 as the active ingredient.

19. A process for preparing RANTES mutants of claims 1-12 which comprises culturing eukaryotic cells trasfected with vectors containing
5 DNA fragments encoding said mutants.

20. A process according to claim 19, wherein said vector is a baculovirus expression vector.

21. A process according to claim 19, wherein said vector is a E. coli expression vector.

10 22. The use of wild-type RANTES added with a residue of Leu at the N-terminus (Leu(0) RANTES), for the preparation of a medicament having anti-HIV activity.

PBMC INFECTION with HIV-1₆₃₆₆ isolate

FIGURE 2




FIGURE 3






FIGURE 4




Desensitization of the receptors by pVU15

FIGURE 5



Desensitization of the receptors by pVU17



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/08354

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/19 C07K14/52 A61K38/19 C12N5/10 C12N1/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEEPIKA R. PAKIANATHAN ET AL: "Distinct but overlapping epitopes for the interaction of a CC-Chemokine with CCR1, CCR3, and CCR5" BIOCHEMISTRY., vol. 36, 12 August 1997, pages 9642-9648, XP002106002 EASTON, PA US see the whole document --- -/--	1-4,7, 15,16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 June 1999

Date of mailing of the international search report

30/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Le Cornec, N

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/08354

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PROUDFOOT A E I ET AL: "EXTENSION OF RECOMBINANT HUMAN RANTES BY THE RETENTION OF THE INITIATING METHIONINE PRODUCES A POTENT ANTAGONIST" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 5, 2 February 1996, pages 2599-2603, XP002056060 see page 2599 see page 2602</p> <p>---</p>	12, 14-22
A	<p>WO 97 44462 A (INSTITUT PASTEUR) 27 November 1997 see page 15, line 20 - line 27; claims see page 11, line 16 - line 23</p> <p>---</p>	1-12, 14-22
A	<p>WO 96 17935 A (GLAXO GROUP LIMITED) 13 June 1996 cited in the application see page 14, line 1 - page 19</p> <p>---</p>	1-12, 14-22
A	<p>CHUN-WA CHUNG ET AL: "The three-Dimensional solution structure of RANTES" BIOCHEMISTRY., vol. 34, 1995, pages 9307-9314, XP002106003 EASTON, PA US cited in the application see the whole document</p> <p>---</p>	1-12, 14-22
A	<p>GONG J -H ET AL: "RANTES AND MCP-3 ANTAGONISTS BIND MULTIPLE CHEMOKINE RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 18, 3 May 1996, pages 10521-10527, XP002047804</p> <p>---</p>	
A	<p>SKELTON N J ET AL: "PROTON NMR ASSIGNMENTS AND SOLUTION CONFORMATION OF RANTES, A CHEMOKINE OF THE C-C TYPE" BIOCHEMISTRY, vol. 34, no. 16, 25 April 1995, pages 5329-5342, XP002054438 see the whole document</p> <p>-----</p>	1-12, 14-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/08354

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 13
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claim 13 has not been searched because a peptide derived from RANTES has not been characterized.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/08354

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9744462 A	27-11-1997	FR 2748938 A	28-11-1997
		AU 3036997 A	09-12-1997
WO 9617935 A	13-06-1996	AU 688641 B	12-03-1998
		AU 4120896 A	26-06-1996
		BR 9509890 A	30-12-1997
		CA 2207036 A	13-06-1996
		CN 1168697 A	24-12-1997
		CZ 9701719 A	12-11-1997
		EP 0796330 A	24-09-1997
		FI 972433 A	06-06-1997
		HU 77075 A	02-03-1998
		JP 10510151 T	06-10-1998
		NO 972620 A	06-08-1997
		NZ 296570 A	25-11-1998
		PL 320565 A	13-10-1997